fluticasone furoate/umeclidinium/vilanterol vs Olodaterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT02164513 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).

Next expected readout: September 2027 · NCT07192016 (registry estimate)

Reported efficacy

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)

Result source: NCT02164513

Olodaterol

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT00782210 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled phase 3 trial in 624 patients with COPD comparing two doses of olodaterol (5 mcg and 10 mcg once daily) against placebo. Both pre-specified co-primary endpoints—FEV1 AUC 0-3h and trough FEV1 at 12 weeks—were met for both doses, with large, statistically significant differences versus placebo (p<0.0001 for all primary comparisons). The trial was adequately powered, used a regulator-accepted lung function endpoint for COPD, and the primary results were clearly positive.

Reported efficacy

Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks) (1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Day 85); Trough FEV1 Response at Day 85 (12 Weeks) (1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h and - 10 mins prior to study drug at Day 85.): FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624). (met)

Result source: NCT00782210

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolOlodaterol
Moderate or severe exacerbations, annualised rate0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
0.6 vs 0.7−0.1 vs placebo10 mcg qd · wk 48 · n 234NCT00796653
3 other results
  • 0.7 vs 0.6 10 mcg qd · wk 48 · n 225 · Phase 3 · secondary NCT00793624
  • 0.5 vs 0.7 5 mcg qd · wk 48 · n 232 · Phase 3 · secondary NCT00796653
  • 0.7 vs 0.6 5 mcg qd · wk 48 · n 227 · Phase 3 · secondary NCT00793624
Trough FEV1, change0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
0.0 vs -0.1+0.1 vs placebo10 mcg qd · wk 24 · n 228NCT00796653
105 other results
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 219 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 202 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 207 · Phase 3 · primary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 24 · n 229 · Phase 3 · primary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 220 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 199 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 205 · Phase 3 · primary NCT00782509
  • 0.2 vs 0.0 5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.0 2.5 μg + 5 μg · wk 12 · n 201 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 2.5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.1 5 μg and 18 μg · wk 12 · n 550 · Phase 3 · primary NCT01696058
  • 0.2 vs 0.1 5µg olodaterol + 18µg tiotropium · wk 12 · n 548 · Phase 3 · primary NCT01694771
  • 0.0 vs -0.7 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 228 · Phase 3 · secondary NCT00796653
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 40 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 32 · n 202 · Phase 3 · secondary NCT00782210
  • -0.0 vs -0.0 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 24 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 18 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 99 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 107 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 10 mcg qd · wk 6 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 90 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 10 mcg qd · wk 2 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.7 5 mcg qd · wk 48 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 205 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 48 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 40 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 32 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 24 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 100 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 115 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 92 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 5 mcg qd · wk 2 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 220 · Phase 3 · secondary NCT00793624
  • 0.2 vs 0.1 2.5/5 · wk 6 · n 214 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 5/5 · wk 6 · n 216 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 2.5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs 0.1 5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs -0.0 10mcg · wk 4 · n 86 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 4 · n 86 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 5mcg · wk 4 · n 79 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 4 · n 80 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 4 · n 79 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 2mcg · wk 4 · n 84 · Phase 2 · primary NCT00824382
  • 0.0 vs -0.0 2 mcg qd · wk 4 · n 81 · Phase 2 · primary NCT00452400
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 10mcg · wk 2 · n 86 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 10 mcg qd · wk 1 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.1 5μg/5μg · wk 4 · n 50 · Phase 4 · secondary NCT04223843
  • 0.2 vs -0.1 5μg/5μg · wk 4 · n 47 · Phase 4 · secondary NCT04223843
  • 0.1 vs -0.0 5mcg · wk 2 · n 79 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 5 mcg qd · wk 1 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 2 · n 79 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 1 · n 79 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 6 mg · wk 0.4286 · n 73 · Phase 2 · secondary NCT03673670
  • 0.1 vs -0.0 2mcg · wk 2 · n 84 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 2 mcg qd · wk 2 · n 81 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 2 mcg qd · wk 1 · n 81 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 1.5 mg · wk 0.4286 · n 74 · Phase 2 · secondary NCT03673670
  • 0.1 vs 0.1 5μg/5μg · wk 12 · n 145 · Phase 4 · secondary NCT03240575
SGRQ total, change-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
37.1 vs 42.0−4.9 vs placebo5 μg + 5 μg · wk 12 · n 196NCT01964352
22 other results
  • 38.0 vs 42.6 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · primary NCT02006732
  • 37.6 vs 42.3 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · primary NCT02006732
  • 37.9 vs 42.0 2.5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT01964352
  • 38.9 vs 42.6 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · primary NCT02006732
  • 38.4 vs 42.3 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · primary NCT02006732
  • 38.6 vs 42.1 10 mcg qd · wk 24 · n 212 · Phase 3 · secondary NCT00796653
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00796653
  • 37.7 vs 41.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00793624
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00793624
  • 40.2 vs 42.7 10 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00796653
  • 37.0 vs 42.1 10 mcg qd · wk 12 · n 202 · Phase 3 · secondary NCT00793624
  • 38.8 vs 39.9 10 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00796653
  • 36.9 vs 40.4 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00793624
  • 39.0 vs 42.1 5 mcg qd · wk 24 · n 216 · Phase 3 · secondary NCT00796653
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00796653
  • 41.2 vs 43.1 5 μg and 18 μg · wk 12 · n 1039 · Phase 3 · secondary NCT01696058
  • 38.6 vs 41.1 5 mcg qd · wk 24 · n 200 · Phase 3 · secondary NCT00793624
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00793624
  • 40.1 vs 42.7 5 mcg qd · wk 12 · n 216 · Phase 3 · secondary NCT00796653
  • 39.3 vs 42.1 5 mcg qd · wk 12 · n 200 · Phase 3 · secondary NCT00793624
  • 39.6 vs 39.9 5 mcg qd · wk 48 · n 216 · Phase 3 · secondary NCT00796653
  • 38.5 vs 40.4 5 mcg qd · wk 48 · n 200 · Phase 3 · secondary NCT00793624
TDI focal score2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
1.5 vs 1.1+0.4 vs placebo10 mcg qd · wk 24 · n 220NCT00796653
35 other results
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00796653
  • 2.1 vs 2.0 10 mcg qd · wk 24 · n 207 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 24 · n 221 · Phase 3 · primary NCT00796653
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00796653
  • 2.2 vs 2.0 5 mcg qd · wk 24 · n 212 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00793624
  • 1.5 vs 1.0 10 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00796653
  • 2.1 vs 1.7 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.2 10 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.7 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 10 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.4 10 mcg qd · wk 12 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 10 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00796653
  • 1.9 vs 2.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00793624
  • 1.8 vs 1.1 10 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00796653
  • 2.3 vs 1.9 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.0 5 mcg qd · wk 18 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 18 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.2 5 mcg qd · wk 32 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 32 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 5 mcg qd · wk 12 · n 221 · Phase 3 · secondary NCT00796653
  • 1.5 vs 0.3 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · secondary NCT02006732
  • 1.8 vs 1.4 5 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.1 5 mcg qd · wk 40 · n 221 · Phase 3 · secondary NCT00796653
  • 1.8 vs 2.0 5 mcg qd · wk 40 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.0 5 mcg qd · wk 6 · n 221 · Phase 3 · secondary NCT00796653
  • 1.6 vs 1.0 5 mcg qd · wk 6 · n 212 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 48 · n 221 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.9 5 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00793624
  • 1.6 vs 0.3 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · secondary NCT02006732

Moderate or severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
Olodaterol
0.6 vs 0.7−0.1 vs placebo10 mcg qd · wk 48 · n 234NCT00796653
3 other results
  • 0.7 vs 0.6 10 mcg qd · wk 48 · n 225 · Phase 3 · secondary NCT00793624
  • 0.5 vs 0.7 5 mcg qd · wk 48 · n 232 · Phase 3 · secondary NCT00796653
  • 0.7 vs 0.6 5 mcg qd · wk 48 · n 227 · Phase 3 · secondary NCT00793624

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
Olodaterol
0.0 vs -0.1+0.1 vs placebo10 mcg qd · wk 24 · n 228NCT00796653
105 other results
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 219 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 202 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 207 · Phase 3 · primary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 24 · n 229 · Phase 3 · primary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 220 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 199 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 205 · Phase 3 · primary NCT00782509
  • 0.2 vs 0.0 5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.0 2.5 μg + 5 μg · wk 12 · n 201 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 2.5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.1 5 μg and 18 μg · wk 12 · n 550 · Phase 3 · primary NCT01696058
  • 0.2 vs 0.1 5µg olodaterol + 18µg tiotropium · wk 12 · n 548 · Phase 3 · primary NCT01694771
  • 0.0 vs -0.7 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 228 · Phase 3 · secondary NCT00796653
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 40 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 32 · n 202 · Phase 3 · secondary NCT00782210
  • -0.0 vs -0.0 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 24 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 18 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 99 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 107 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 10 mcg qd · wk 6 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 90 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 10 mcg qd · wk 2 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.7 5 mcg qd · wk 48 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 205 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 48 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 40 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 32 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 24 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 100 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 115 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 92 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 5 mcg qd · wk 2 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 220 · Phase 3 · secondary NCT00793624
  • 0.2 vs 0.1 2.5/5 · wk 6 · n 214 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 5/5 · wk 6 · n 216 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 2.5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs 0.1 5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs -0.0 10mcg · wk 4 · n 86 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 4 · n 86 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 5mcg · wk 4 · n 79 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 4 · n 80 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 4 · n 79 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 2mcg · wk 4 · n 84 · Phase 2 · primary NCT00824382
  • 0.0 vs -0.0 2 mcg qd · wk 4 · n 81 · Phase 2 · primary NCT00452400
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 10mcg · wk 2 · n 86 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 10 mcg qd · wk 1 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.1 5μg/5μg · wk 4 · n 50 · Phase 4 · secondary NCT04223843
  • 0.2 vs -0.1 5μg/5μg · wk 4 · n 47 · Phase 4 · secondary NCT04223843
  • 0.1 vs -0.0 5mcg · wk 2 · n 79 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 5 mcg qd · wk 1 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 2 · n 79 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 1 · n 79 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 6 mg · wk 0.4286 · n 73 · Phase 2 · secondary NCT03673670
  • 0.1 vs -0.0 2mcg · wk 2 · n 84 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 2 mcg qd · wk 2 · n 81 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 2 mcg qd · wk 1 · n 81 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 1.5 mg · wk 0.4286 · n 74 · Phase 2 · secondary NCT03673670
  • 0.1 vs 0.1 5μg/5μg · wk 12 · n 145 · Phase 4 · secondary NCT03240575

SGRQ total, change

fluticasone furoate/​umeclidinium/​vilanterol
-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
Olodaterol
37.1 vs 42.0−4.9 vs placebo5 μg + 5 μg · wk 12 · n 196NCT01964352
22 other results
  • 38.0 vs 42.6 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · primary NCT02006732
  • 37.6 vs 42.3 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · primary NCT02006732
  • 37.9 vs 42.0 2.5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT01964352
  • 38.9 vs 42.6 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · primary NCT02006732
  • 38.4 vs 42.3 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · primary NCT02006732
  • 38.6 vs 42.1 10 mcg qd · wk 24 · n 212 · Phase 3 · secondary NCT00796653
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00796653
  • 37.7 vs 41.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00793624
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00793624
  • 40.2 vs 42.7 10 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00796653
  • 37.0 vs 42.1 10 mcg qd · wk 12 · n 202 · Phase 3 · secondary NCT00793624
  • 38.8 vs 39.9 10 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00796653
  • 36.9 vs 40.4 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00793624
  • 39.0 vs 42.1 5 mcg qd · wk 24 · n 216 · Phase 3 · secondary NCT00796653
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00796653
  • 41.2 vs 43.1 5 μg and 18 μg · wk 12 · n 1039 · Phase 3 · secondary NCT01696058
  • 38.6 vs 41.1 5 mcg qd · wk 24 · n 200 · Phase 3 · secondary NCT00793624
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00793624
  • 40.1 vs 42.7 5 mcg qd · wk 12 · n 216 · Phase 3 · secondary NCT00796653
  • 39.3 vs 42.1 5 mcg qd · wk 12 · n 200 · Phase 3 · secondary NCT00793624
  • 39.6 vs 39.9 5 mcg qd · wk 48 · n 216 · Phase 3 · secondary NCT00796653
  • 38.5 vs 40.4 5 mcg qd · wk 48 · n 200 · Phase 3 · secondary NCT00793624

TDI focal score

fluticasone furoate/​umeclidinium/​vilanterol
2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
Olodaterol
1.5 vs 1.1+0.4 vs placebo10 mcg qd · wk 24 · n 220NCT00796653
35 other results
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00796653
  • 2.1 vs 2.0 10 mcg qd · wk 24 · n 207 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 24 · n 221 · Phase 3 · primary NCT00796653
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00796653
  • 2.2 vs 2.0 5 mcg qd · wk 24 · n 212 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00793624
  • 1.5 vs 1.0 10 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00796653
  • 2.1 vs 1.7 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.2 10 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.7 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 10 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.4 10 mcg qd · wk 12 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 10 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00796653
  • 1.9 vs 2.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00793624
  • 1.8 vs 1.1 10 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00796653
  • 2.3 vs 1.9 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.0 5 mcg qd · wk 18 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 18 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.2 5 mcg qd · wk 32 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 32 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 5 mcg qd · wk 12 · n 221 · Phase 3 · secondary NCT00796653
  • 1.5 vs 0.3 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · secondary NCT02006732
  • 1.8 vs 1.4 5 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.1 5 mcg qd · wk 40 · n 221 · Phase 3 · secondary NCT00796653
  • 1.8 vs 2.0 5 mcg qd · wk 40 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.0 5 mcg qd · wk 6 · n 221 · Phase 3 · secondary NCT00796653
  • 1.6 vs 1.0 5 mcg qd · wk 6 · n 212 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 48 · n 221 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.9 5 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00793624
  • 1.6 vs 0.3 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · secondary NCT02006732
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · Olodaterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterol
Rows use multiple source trials
Olodaterol
Rows use multiple source trials
Dropout rate
10.5%FF/UMEC/VIa
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
4.9%100/62.5/25 µg
NCT02345161 · Phase 3
6.1%
NCT04923347 · Phase 4 · registry result, not featured evidence
9.5%
NCT05535972 · Phase 4 · registry result, not featured evidence
3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
4.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.6%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
3.6%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
—10 mcga
NCT00782210 · Phase 3
show 77 more results
16.9%10 mcg qd
NCT00782210 · Phase 3
—5 mcg
NCT00782210 · Phase 3
16.8%5 mcg qd
NCT00782210 · Phase 3
—10 mcg
NCT00782509 · Phase 3
16.6%10 mcg qd
NCT00782509 · Phase 3
—5 mcg
NCT00782509 · Phase 3
11.5%5 mcg qd
NCT00782509 · Phase 3
15.4%10 mcg qd
NCT00796653 · Phase 3
15.9%5 mcg qd
NCT00796653 · Phase 3
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
1.4%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5/5 μg
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
0%5/5 mcg
NCT02683109 · Phase 4 · registry result, not featured evidence
—5/5
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
13.2%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
6.6%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
—2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
—5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
3.9%5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
3%2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2%5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
4.5%2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
7.6%5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
5.3%2.5 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—2.5 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
4.3%5.0 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—5.0 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
5%2.5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
4.9%5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
7.1%5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
17.3%10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
15.9%5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
5.8%10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
3.8%5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
2.4%2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
—10 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—2 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
4.5%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
1.2%10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
8.8%5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—20 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
3.8%20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—2 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
1.2%2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.9%FF/UMEC/VIa
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
1.8%100/62.5/25 µg
NCT02345161 · Phase 3
—
NCT04923347 · Phase 4 · registry result, not featured evidence
1.3%
NCT05535972 · Phase 4 · registry result, not featured evidence
0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
1.5%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.3%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
1.4%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
—10 mcga
NCT00782210 · Phase 3
show 77 more results
7.7%10 mcg qd
NCT00782210 · Phase 3
—5 mcg
NCT00782210 · Phase 3
8.2%5 mcg qd
NCT00782210 · Phase 3
—10 mcg
NCT00782509 · Phase 3
9.2%10 mcg qd
NCT00782509 · Phase 3
—5 mcg
NCT00782509 · Phase 3
4.8%5 mcg qd
NCT00782509 · Phase 3
6.8%10 mcg qd
NCT00796653 · Phase 3
6.9%5 mcg qd
NCT00796653 · Phase 3
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5/5 μg
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
0%5/5 mcg
NCT02683109 · Phase 4 · registry result, not featured evidence
—5/5
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
6.6%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
5.3%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
—2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
—5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
1.5%5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
1%5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
3.7%5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
5.3%2.5 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—2.5 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
3.6%5.0 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—5.0 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
2.5%2.5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
4.9%5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
3.2%5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
6.7%10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
7%5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.7%10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
1.3%5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
1.2%2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
—10 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—2 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
1.1%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
0%10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
6.3%5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—20 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—2 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
1.2%2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
Serious AEs
—FF/UMEC/VIa
NCT02164513 · Phase 3
show 9 more results
21.6%100/62.5/25
NCT02164513 · Phase 3
6.7%100/62.5/25 µg
NCT02345161 · Phase 3
0.4%
NCT04923347 · Phase 4 · registry result, not featured evidence
4.1%
NCT05535972 · Phase 4 · registry result, not featured evidence
7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
3.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.4%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
8%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
20.8%10 mcga
NCT00782210 · Phase 3
show 77 more results
—10 mcg qd
NCT00782210 · Phase 3
18.8%5 mcg
NCT00782210 · Phase 3
—5 mcg qd
NCT00782210 · Phase 3
17.1%10 mcg
NCT00782509 · Phase 3
—10 mcg qd
NCT00782509 · Phase 3
15.3%5 mcg
NCT00782509 · Phase 3
—5 mcg qd
NCT00782509 · Phase 3
17.5%10 mcg qd
NCT00796653 · Phase 3
14.7%5 mcg qd
NCT00796653 · Phase 3
1.9%5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
3.9%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
4.8%5/5 μg
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
1.8%5/5 mcg
NCT02683109 · Phase 4 · registry result, not featured evidence
3.9%5/5
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
10.5%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
3.9%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
2.8%2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
3.2%5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
4.9%5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
—5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
3%5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
4.2%5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
—2.5 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
6.8%2.5 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—5.0 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
2.9%5.0 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
15%2.5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
7.3%5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
7.1%5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
2.1%10 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
2%5 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
2%10 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
5.3%5 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
0%10 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
1%5 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
7.1%10 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
2.6%5 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
11.6%10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
14.5%5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3.2%10 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
4.3%5 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
1.4%6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0%1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
1.8%10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
3.7%5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0%tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
2.7%tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
3.5%10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
1.3%5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
3.6%2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0%10 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
0%5 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
0%5 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
2.1%2 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
0%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.4%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.3%10 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%5 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%20 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%2 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100/62.5/25a
viral upper respiratory tract infection 12.5%
upper respiratory tract infection 7.2%
headache 5.6%
NCT02164513 · Phase 3
show 8 more results
100/62.5/25 µg
nasopharyngitis 7.9%
headache 4.8%
NCT02345161 · Phase 3
pyrexia 4.4%
headache 3.9%
NCT04923347 · Phase 4 · registry result, not featured evidence
dysphonia 0.4%
abdominal discomfort 0.2%
abdominal pain upper 0.2%
NCT05535972 · Phase 4 · registry result, not featured evidence
100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
dyspnoea 2.1%
NCT03467425 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 4.5%
nasopharyngitis 4%
NCT03474081 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 3.6%
nasopharyngitis 1.9%
NCT03478696 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 5%
NCT03478683 · Phase 4 · registry result, not featured evidence
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
10 mcga
chronic obstructive pulmonary disease 23.7% (placebo 27.3%)
nasopharyngitis 6.3% (placebo 6.2%)
upper respiratory tract infection 6.3% (placebo 7.2%)
NCT00782210 · Phase 3
show 57 more results
5 mcg
chronic obstructive pulmonary disease 19.2% (placebo 27.3%)
nasopharyngitis 10.1% (placebo 6.2%)
upper respiratory tract infection 10.1% (placebo 7.2%)
NCT00782210 · Phase 3
10 mcg
chronic obstructive pulmonary disease 21.7% (placebo 19.9%)
nasopharyngitis 11.5% (placebo 8.3%)
upper respiratory tract infection 10.1% (placebo 7.9%)
NCT00782509 · Phase 3
5 mcg
chronic obstructive pulmonary disease 18.7% (placebo 19.9%)
upper respiratory tract infection 9.6% (placebo 7.9%)
nasopharyngitis 9.1% (placebo 8.3%)
NCT00782509 · Phase 3
10 mcg qd
chronic obstructive pulmonary disease 20.5% (placebo 21.7%)
nasopharyngitis 12% (placebo 9.4%)
upper respiratory tract infection 6.4% (placebo 7.7%)
NCT00796653 · Phase 3
5 mcg qd
chronic obstructive pulmonary disease 17.2% (placebo 21.7%)
nasopharyngitis 15.5% (placebo 9.4%)
upper respiratory tract infection 6% (placebo 7.7%)
NCT00796653 · Phase 3
5μg/5μg
chronic obstructive pulmonary disease 5.3%
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
5/5 μg
chronic obstructive pulmonary disease 13.3%
viral upper respiratory tract infection 13.3%
cough 4.8%
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
5/5 mcg
chronic obstructive pulmonary disease 8.1%
NCT02683109 · Phase 4 · registry result, not featured evidence
5/5
viral upper respiratory tract infection 10%
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
5/5 μg
chronic obstructive pulmonary disease 17.1% (placebo 21.3%)
nasopharyngitis 13.2% (placebo 10.7%)
dyspnoea 2.6% (placebo 2.7%)
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
5/5 μg
chronic obstructive pulmonary disease 15.8% (placebo 21.3%)
nasopharyngitis 5.3% (placebo 10.7%)
back pain 2.6% (placebo 5.3%)
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
2.5/5
nasopharyngitis 5.6%
chronic obstructive pulmonary disease 4.7%
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
5/5
chronic obstructive pulmonary disease 8.1%
nasopharyngitis 5.4%
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
5 μg + 5 μg
chronic obstructive pulmonary disease 4.4% (placebo 9.8%)
nasopharyngitis 3.4% (placebo 5.9%)
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2.5 μg + 5 μg
chronic obstructive pulmonary disease 7.9% (placebo 9.8%)
nasopharyngitis 4.5% (placebo 5.9%)
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
5 μg + 5 μg
chronic obstructive pulmonary disease 4.5% (placebo 6.9%)
cough 1.5% (placebo 5.9%)
dyspnoea 1% (placebo 6.9%)
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
2.5 μg + 5 μg
chronic obstructive pulmonary disease 8.4% (placebo 6.9%)
cough 2.5% (placebo 5.9%)
dyspnoea 2% (placebo 6.9%)
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
5 μg and 18 μg
chronic obstructive pulmonary disease 8.5% (placebo 7.7%)
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
2.5 / 5.0 μg
chronic obstructive pulmonary disease 7.5% (placebo 11.4%)
cough 6.8% (placebo 6.1%)
nasopharyngitis 6.8% (placebo 4.5%)
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
5.0 / 5.0 μg
chronic obstructive pulmonary disease 7.2% (placebo 11.4%)
nasopharyngitis 2.9% (placebo 4.5%)
cough 1.4% (placebo 6.1%)
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
2.5 / 5 μg
nasopharyngitis 27.5%
bronchitis 12.5%
chronic obstructive pulmonary disease 10%
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
5 / 5 μg
nasopharyngitis 26.8%
chronic obstructive pulmonary disease 17.1%
bronchitis 14.6%
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
5µg olodaterol + 18µg tiotropium
chronic obstructive pulmonary disease 10.6%
NCT01694771 · Phase 3 · registry result, not featured evidence
10 mcg
chronic obstructive pulmonary disease 3.5% (placebo 5.6%)
NCT01040130 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 6.8% (placebo 5.6%)
NCT01040130 · Phase 3 · registry result, not featured evidence
10 mcg
chronic obstructive pulmonary disease 2.7% (placebo 6%)
NCT01040793 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 5.3% (placebo 6%)
NCT01040793 · Phase 3 · registry result, not featured evidence
10 mcg
nasopharyngitis 4% (placebo 7.8%)
chronic obstructive pulmonary disease 2% (placebo 3.9%)
NCT01040689 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 7.9% (placebo 3.9%)
nasopharyngitis 5.9% (placebo 7.8%)
NCT01040689 · Phase 3 · registry result, not featured evidence
10 mcg
nasopharyngitis 3.5% (placebo 3.7%)
chronic obstructive pulmonary disease 2.7% (placebo 3.7%)
NCT01040728 · Phase 3 · registry result, not featured evidence
5 mcg
nasopharyngitis 7% (placebo 3.7%)
chronic obstructive pulmonary disease 5.2% (placebo 3.7%)
NCT01040728 · Phase 3 · registry result, not featured evidence
10 mcg qd
chronic obstructive pulmonary disease 27.6% (placebo 22.7%)
nasopharyngitis 11.1% (placebo 6.7%)
cough 5.8% (placebo 3.1%)
NCT00793624 · Phase 3 · registry result, not featured evidence
5 mcg qd
chronic obstructive pulmonary disease 29.5% (placebo 22.7%)
nasopharyngitis 9.7% (placebo 6.7%)
upper respiratory tract infection 7.5% (placebo 6.7%)
NCT00793624 · Phase 3 · registry result, not featured evidence
10 mcg
chronic obstructive pulmonary disease 7.4% (placebo 5.3%)
upper respiratory tract infection 5.3% (placebo 4.3%)
NCT00932646 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 5.4% (placebo 5.3%)
upper respiratory tract infection 4.3% (placebo 4.3%)
NCT00932646 · Phase 3 · registry result, not featured evidence
6 mg
headache 6.8% (placebo 1.3%)
ventricular extrasystoles 4.1% (placebo 0%)
chronic obstructive pulmonary disease 2.7% (placebo 1.3%)
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
1.5 mg
headache 6.7% (placebo 1.3%)
ventricular extrasystoles 2.7% (placebo 0%)
accelerated idioventricular rhythm 1.3% (placebo 0%)
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
nasopharyngitis 1.9% (placebo 5.7%)
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
10 mcg
nasopharyngitis 6.4%
chronic obstructive pulmonary disease 5.5%
NCT01040403 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 10.2%
chronic obstructive pulmonary disease 5.6%
NCT01040403 · Phase 2 · registry result, not featured evidence
tiotropium 5 mcg + olodaterol 10 mcg
chronic obstructive pulmonary disease 3.6%
nasopharyngitis 1.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 5 mcg + olodaterol 5 mcg
chronic obstructive pulmonary disease 7.3%
nasopharyngitis 2.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 10 mcg
nasopharyngitis 3.6%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 5 mcg
nasopharyngitis 7.1%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 10 mcg
nasopharyngitis 7.3%
chronic obstructive pulmonary disease 6.4%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 5 mcg
nasopharyngitis 11%
chronic obstructive pulmonary disease 3.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
10mcg
nasopharyngitis 5.8% (placebo 3.8%)
myalgia 0% (placebo 5.1%)
NCT00824382 · Phase 2 · registry result, not featured evidence
5mcg
nasopharyngitis 3.8% (placebo 3.8%)
myalgia 0% (placebo 5.1%)
NCT00824382 · Phase 2 · registry result, not featured evidence
2mcg
nasopharyngitis 10.7% (placebo 3.8%)
myalgia 0% (placebo 5.1%)
NCT00824382 · Phase 2 · registry result, not featured evidence
10 mcg qd
nasopharyngitis 6.5%
dyspnoea 0%
NCT00846768 · Phase 2 · registry result, not featured evidence
5 mcg Bid
nasopharyngitis 6.5%
dyspnoea 2.2%
NCT00846768 · Phase 2 · registry result, not featured evidence
5 mcg qd
dyspnoea 6.4%
nasopharyngitis 2.1%
NCT00846768 · Phase 2 · registry result, not featured evidence
2 mcg Bid
nasopharyngitis 2.1%
dyspnoea 0%
NCT00846768 · Phase 2 · registry result, not featured evidence
10 mcg
nasopharyngitis 4.7% (placebo 1.3%)
headache 3.5% (placebo 5.1%)
cough 2.3% (placebo 2.5%)
NCT00452400 · Phase 2 · registry result, not featured evidence
5 mcg
cough 7.5% (placebo 2.5%)
nasopharyngitis 7.5% (placebo 1.3%)
dyspnoea 2.5% (placebo 7.6%)
NCT00452400 · Phase 2 · registry result, not featured evidence
20 mcg
dyspnoea 3.8% (placebo 7.6%)
cough 2.5% (placebo 2.5%)
nasopharyngitis 2.5% (placebo 1.3%)
NCT00452400 · Phase 2 · registry result, not featured evidence
2 mcg
cough 4.9% (placebo 2.5%)
dyspnoea 3.7% (placebo 7.6%)
headache 3.7% (placebo 5.1%)
NCT00452400 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

Time to First Moderate or Severe Exacerbation NA vs NA FF/VI months @ 52wk
time to event · months
Median time to onset
NCT02164513 · Phase 3
show 1 more result
NA vs 8.31 UMEC/VI months @ 52wk
Median time to onset
NCT02164513 · Phase 3
EXACT-RS -1.45 vs -0.5 BUD/FOR score @ 4wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 17 more results
-2 vs -0.77 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.23 vs -1.05 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.42 vs -1.09 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.43 vs -1.02 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.31 vs -0.96 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.24 vs -0.72 BUD/FOR score @ 4wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.97 vs -0.9 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.18 vs -1.21 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.53 vs -1.52 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.64 vs -1.53 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.63 vs -1.52 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.48 vs -1.16 BUD/FOR score @ 28wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.33 vs -0.9 BUD/FOR score @ 32wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.12 vs -0.62 BUD/FOR score @ 36wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.34 vs -1.11 BUD/FOR score @ 40wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.3 vs -0.81 BUD/FOR score @ 44wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.17 vs -0.64 BUD/FOR score @ 48wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -2.03 vs -0.61 BUD/FOR score @ 52wk100/62.5/25 µg
absolute change · score
EXACT-RS Scores, Week 49-52, n=179, 171
NCT02345161 · Phase 3
FEV1 Trough 0.0542 L @ 4wk
absolute change · L
No placebo or comparator arm
CFB to Day 28
NCT04923347 · Phase 4 · registry result, not featured evidence
FEV1 Trough 0.0317 L @ 12wk
absolute change · L
No placebo or comparator arm
CFB to Day 85
NCT04923347 · Phase 4 · registry result, not featured evidence
CAT Total -6.8 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.4 score @ 4wk
NCT05535972 · Phase 4 · registry result, not featured evidence
mMRC Dyspnea Scale -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.5 score @ 12wk
NCT05535972 · Phase 4 · registry result, not featured evidence
FEV1 0.132 L @ 12wk
absolute change · L
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 86% (n=422) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 47.5% (n=1539) vs 39.9% (n=1543) Non-Ellipta @ 24wk100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
responder rate · % of participants
NCT03467425 · Phase 4 · registry result, not featured evidence · converted to % from 731 Participants as posted
FEV1 1.446 vs 1.396 Non-Ellipta L @ 24wk100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
absolute change · L
NCT03467425 · Phase 4 · registry result, not featured evidence
FEV1 Wm0 24 h 0.039 vs 0.029 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
absolute change · L
NCT03478696 · Phase 4 · registry result, not featured evidence
show 5 more results
0.045 vs 0.041 Budesonide/Formoterol Plus Tiotropium L @ 0.14wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.04 vs 0.023 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.045 vs 0.03 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.054 vs 0.063 Budesonide/Formoterol Plus Tiotropium L @ 0.14wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.046 vs 0.032 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

Olodaterol

FEV1 AUC0-3 0.169 vs -0.007 placebo L @ 12wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 68 more results
0.199 vs 0.024 placebo L @ 0wk10 mcg qd
NCT00782210 · Phase 3
0.192 vs 0 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.165 vs -0.001 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.143 vs -0.18 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.126 vs -0.043 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.152 vs 0.008 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.196 vs 0.025 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.177 vs 0.025 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.171 vs 0.01 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.126 vs -0.01 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.128 vs -0.03 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.14 vs -0.013 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.214 vs 0.021 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.181 vs -0.01 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.167 vs -0.008 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.116 vs -0.025 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.191 vs -0.021 placebo L10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.17 vs -0.045 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.256 vs 0.018 placebo L10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.255 vs 0.011 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.156 vs -0.009 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.181 vs 0.015 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.161 vs 0.001 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.167 vs -0.003 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.123 vs -0.023 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.202 vs 0.004 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.173 vs -0.02 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.236 vs 0.031 placebo L @ 0wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.218 vs 0 placebo L @ 1wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.209 vs 0.006 placebo L @ 2wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.165 vs -0.007 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.189 vs 0.024 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.18 vs 0 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.169 vs -0.001 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.156 vs -0.18 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.13 vs -0.043 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.159 vs 0.008 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.189 vs 0.025 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.188 vs 0.025 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.18 vs 0.01 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.155 vs -0.01 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.132 vs -0.03 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.116 vs -0.013 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.181 vs 0.021 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.162 vs -0.01 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.138 vs -0.008 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.093 vs -0.025 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.161 vs -0.021 placebo L5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.161 vs -0.045 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.232 vs 0.018 placebo L5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.225 vs 0.011 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.142 vs -0.009 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.201 vs 0.015 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.178 vs 0.001 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.176 vs -0.003 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.122 vs -0.023 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.19 vs 0.004 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.177 vs -0.02 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.203 vs 0.031 placebo L @ 0wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.215 vs 0 placebo L @ 1wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.2 vs 0.006 placebo L @ 2wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.234 vs 0.031 placebo L @ 0wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.247 vs 0 placebo L @ 1wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.211 vs 0.006 placebo L @ 2wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.118 vs -0.02 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.165 vs 0.031 placebo L @ 0wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.186 vs 0 placebo L @ 1wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.166 vs 0.006 placebo L @ 2wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
FEV1 AUC0-12h 0.139 vs -0.029 placebo L @ 12wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 17 more results
0.1 vs 0.01 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.152 vs -0.054 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.213 vs -0.008 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.152 vs -0.022 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.144 vs -0.029 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.12 vs 0.01 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.237 vs 0.147 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
NA vs 0.147 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0.131 vs -0.054 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.189 vs -0.008 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.15 vs -0.022 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.347 vs 0.337 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.308 vs 0.303 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.39 vs 0.337 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.333 vs 0.303 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.295 vs 0.192 F+S 250/50 L @ 6wk2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
0.317 vs 0.192 F+S 250/50 L @ 6wk5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
FEV1 Peak 0.275 vs 0.104 placebo L @ 0wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 84 more results
0.267 vs 0.077 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.238 vs 0.066 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.236 vs 0.071 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.206 vs 0.055 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.192 vs 0.029 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.276 vs 0.099 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.251 vs 0.104 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.246 vs 0.08 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.217 vs 0.088 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.197 vs 0.062 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.198 vs 0.041 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.278 vs 0.099 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.248 vs 0.066 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.232 vs 0.064 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.211 vs 0.06 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.178 vs 0.052 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.279 vs 0.04 placebo L10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.253 vs 0.019 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.342 vs 0.076 placebo L10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.325 vs 0.082 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.25 vs 0.1 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.234 vs 0.081 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.241 vs 0.082 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.225 vs 0.068 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.193 vs 0.053 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.273 vs 0.076 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.22 vs 0.025 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.295 vs 0.078 placebo L @ 4wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.335 vs 0.104 placebo L @ 0wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.295 vs 0.062 placebo L @ 1wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.282 vs 0.079 placebo L @ 2wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.259 vs 0.104 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.254 vs 0.077 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.238 vs 0.066 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.235 vs 0.071 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.23 vs 0.055 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.198 vs 0.029 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.267 vs 0.099 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.259 vs 0.104 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.252 vs 0.08 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.232 vs 0.088 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.226 vs 0.062 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.197 vs 0.041 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.26 vs 0.099 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.235 vs 0.066 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.206 vs 0.064 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.183 vs 0.06 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.163 vs 0.052 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.341 vs 0.243 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
NA vs 0.243 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0.389 vs 0.27 Placebo and Tiotropium L @ 12wk5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
0.253 vs 0.04 placebo L5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.232 vs 0.019 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.313 vs 0.076 placebo L5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.29 vs 0.082 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.277 vs 0.1 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.248 vs 0.081 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.247 vs 0.082 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.216 vs 0.068 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.192 vs 0.053 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.268 vs 0.076 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.227 vs 0.025 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.247 vs 0.078 placebo L @ 4wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.288 vs 0.104 placebo L @ 0wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.293 vs 0.062 placebo L @ 1wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.267 vs 0.079 placebo L @ 2wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.303 vs 0.078 placebo L @ 4wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.335 vs 0.104 placebo L @ 0wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.321 vs 0.062 placebo L @ 1wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.28 vs 0.079 placebo L @ 2wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.506 vs 0.519 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.467 vs 0.445 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.405 vs 0.324 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.371 vs 0.271 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.17 vs 0.025 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.242 vs 0.078 placebo L @ 4wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.259 vs 0.104 placebo L @ 0wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.264 vs 0.062 placebo L @ 1wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.243 vs 0.079 placebo L @ 2wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.565 vs 0.519 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.49 vs 0.445 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.453 vs 0.324 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.401 vs 0.291 F+S 250/50 L @ 6wk2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
0.432 vs 0.291 F+S 250/50 L @ 6wk5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
FVC AUC(0-3 0.392 vs 0.063 placebo L @ 0wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 59 more results
0.353 vs 0.026 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.316 vs 0.022 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.295 vs 0.003 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.281 vs 0.026 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.231 vs -0.04 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.384 vs 0.052 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.323 vs 0.096 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.294 vs 0.048 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.291 vs 0.046 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.281 vs 0.062 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.271 vs 0.053 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.332 vs 0.082 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.276 vs 0.027 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.253 vs 0.006 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.225 vs 0.012 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.201 vs -0.036 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.288 vs -0.024 placebo L10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.235 vs -0.083 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.419 vs 0.053 placebo L10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.397 vs 0.044 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.311 vs 0.076 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.265 vs 0.016 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.278 vs 0.023 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.252 vs 0.037 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.219 vs 0.016 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.237 vs 0.004 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.35 vs 0.063 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.323 vs 0.026 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.276 vs 0.022 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.277 vs 0.003 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.261 vs 0.026 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.204 vs -0.04 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.383 vs 0.052 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.338 vs 0.096 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.312 vs 0.048 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.284 vs 0.046 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.303 vs 0.062 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.271 vs 0.053 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.312 vs 0.082 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.277 vs 0.027 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.235 vs 0.006 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.212 vs 0.012 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.182 vs -0.036 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.446 vs -0.011 placebo L @ 12wk5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.414 vs -0.018 placebo L @ 12wk5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.244 vs -0.024 placebo L5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.234 vs -0.083 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.423 vs 0.053 placebo L5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.388 vs 0.044 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.299 vs 0.076 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.252 vs 0.016 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.233 vs 0.023 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.22 vs 0.037 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.196 vs 0.016 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.254 vs 0.004 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.387 vs -0.011 placebo L @ 12wk2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.436 vs -0.018 placebo L @ 12wk2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.424 vs 0.306 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.257 vs 0.004 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
FVC Trough 0.169 vs -0.015 placebo L @ 2wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 90 more results
0.135 vs -0.005 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.13 vs -0.03 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.134 vs -0.028 placebo L @ 18wk10 mcg qd
NCT00782210 · Phase 3
0.096 vs -0.028 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.097 vs -0.026 placebo L @ 32wk10 mcg qd
NCT00782210 · Phase 3
0.111 vs -0.044 placebo L @ 40wk10 mcg qd
NCT00782210 · Phase 3
0.032 vs -0.083 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.141 vs 0.054 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.147 vs 0.029 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.091 vs 0.043 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.098 vs 0.064 placebo L @ 18wk10 mcg qd
NCT00782509 · Phase 3
0.091 vs 0.021 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.058 vs 0.061 placebo L @ 32wk10 mcg qd
NCT00782509 · Phase 3
0.131 vs 0.062 placebo L @ 40wk10 mcg qd
NCT00782509 · Phase 3
0.054 vs -0.008 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.173 vs 0.03 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.101 vs -0.014 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.062 vs -0.041 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.107 vs -0.014 placebo L @ 18wk10 mcg qd
NCT00796653 · Phase 3
0.019 vs -0.044 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.063 vs -0.007 placebo L @ 32wk10 mcg qd
NCT00796653 · Phase 3
0.105 vs -0.016 placebo L @ 40wk10 mcg qd
NCT00796653 · Phase 3
0.032 vs -0.069 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.13 vs -0.082 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.215 vs -0.001 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.119 vs 0.042 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.085 vs -0.046 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.087 vs -0.018 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.078 vs 0.06 placebo L @ 18wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.064 vs -0.018 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.084 vs 0.019 placebo L @ 32wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
-0.002 vs -0.061 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.086 vs 0.028 placebo L @ 40wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.133 vs -0.007 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.15 vs -0.037 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.149 vs -0.02 placebo L @ 1wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.149 vs 0 placebo L @ 2wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.146 vs -0.026 placebo L @ 4wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.132 vs -0.015 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.125 vs -0.005 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.085 vs -0.03 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.102 vs -0.028 placebo L @ 18wk5 mcg qd
NCT00782210 · Phase 3
0.055 vs -0.028 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.065 vs -0.026 placebo L @ 32wk5 mcg qd
NCT00782210 · Phase 3
0.087 vs -0.044 placebo L @ 40wk5 mcg qd
NCT00782210 · Phase 3
0.011 vs -0.083 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.113 vs 0.054 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.122 vs 0.029 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.075 vs 0.043 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.114 vs 0.064 placebo L @ 18wk5 mcg qd
NCT00782509 · Phase 3
0.066 vs 0.021 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.099 vs 0.061 placebo L @ 32wk5 mcg qd
NCT00782509 · Phase 3
0.104 vs 0.062 placebo L @ 40wk5 mcg qd
NCT00782509 · Phase 3
0.038 vs -0.008 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.118 vs 0.03 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.113 vs -0.014 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.062 vs -0.041 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.084 vs -0.014 placebo L @ 18wk5 mcg qd
NCT00796653 · Phase 3
0.023 vs -0.044 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.081 vs -0.007 placebo L @ 32wk5 mcg qd
NCT00796653 · Phase 3
0.071 vs -0.016 placebo L @ 40wk5 mcg qd
NCT00796653 · Phase 3
0.012 vs -0.069 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.244 vs 0.025 placebo L @ 12wk5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.231 vs -0.021 placebo L @ 12wk5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.276 vs 0.213 Placebo and Tiotropium L @ 12wk5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
0.103 vs -0.082 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.243 vs -0.001 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.11 vs 0.042 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.065 vs -0.046 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.079 vs -0.018 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.066 vs 0.06 placebo L @ 18wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.038 vs -0.018 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.08 vs 0.019 placebo L @ 32wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.022 vs -0.061 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.087 vs 0.028 placebo L @ 40wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.125 vs -0.007 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.154 vs -0.037 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.154 vs -0.02 placebo L @ 1wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.171 vs 0 placebo L @ 2wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.136 vs -0.026 placebo L @ 4wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.233 vs 0.025 placebo L @ 12wk2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.284 vs -0.021 placebo L @ 12wk2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.151 vs -0.02 placebo L @ 1wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.148 vs 0 placebo L @ 2wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.153 vs -0.026 placebo L @ 4wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.269 vs 0.235 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.154 vs -0.037 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.09 vs -0.02 placebo L @ 1wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.09 vs 0 placebo L @ 2wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.068 vs -0.026 placebo L @ 4wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
FVC Peak 0.546 vs 0.245 placebo L @ 0wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 58 more results
0.499 vs 0.207 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.46 vs 0.18 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.43 vs 0.169 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.42 vs 0.188 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.369 vs 0.109 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.535 vs 0.202 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.464 vs 0.254 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.434 vs 0.183 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.422 vs 0.213 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.429 vs 0.223 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.419 vs 0.208 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.476 vs 0.247 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.417 vs 0.196 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.396 vs 0.171 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.369 vs 0.189 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.352 vs 0.137 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.383 vs 0.086 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.537 vs 0.191 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.474 vs 0.268 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.433 vs 0.202 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.432 vs 0.194 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.414 vs 0.207 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.371 vs 0.193 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.44 vs 0.138 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.335 vs 0.109 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.449 vs 0.152 placebo L @ 4wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.509 vs 0.245 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.471 vs 0.207 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.43 vs 0.18 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.421 vs 0.169 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.419 vs 0.188 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.356 vs 0.109 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.534 vs 0.202 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.479 vs 0.254 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.451 vs 0.183 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.439 vs 0.213 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.449 vs 0.223 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.415 vs 0.208 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.48 vs 0.247 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.443 vs 0.196 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.386 vs 0.171 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.371 vs 0.189 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.325 vs 0.137 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.586 vs 0.433 Placebo and Tiotropium L @ 12wk5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
0.386 vs 0.086 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.526 vs 0.191 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.454 vs 0.268 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.411 vs 0.202 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.382 vs 0.194 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.379 vs 0.207 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.344 vs 0.193 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.436 vs 0.138 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.351 vs 0.109 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.432 vs 0.152 placebo L @ 4wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.438 vs 0.152 placebo L @ 4wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.562 vs 0.457 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.362 vs 0.109 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.44 vs 0.152 placebo L @ 4wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
FVC AUC(0-12h 0.23 vs -0.019 placebo L @ 12wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 9 more results
0.212 vs 0.057 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.192 vs -0.11 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.321 vs -0.006 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.214 vs -0.032 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.283 vs -0.019 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.199 vs 0.057 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.172 vs -0.11 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.324 vs -0.006 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.219 vs -0.032 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
PEF Weekly Avg Morning 195.475 vs 180.019 placebo L/min10 mcg qd
absolute value · L/min
NCT00782210 · Phase 3
show 15 more results
203.873 vs 182.939 placebo L/min10 mcg qd
NCT00782509 · Phase 3
193.376 vs 180.019 placebo L/min5 mcg qd
NCT00782210 · Phase 3
196.3 vs 182.939 placebo L/min5 mcg qd
NCT00782509 · Phase 3
248.76 vs 227.81 Tiotropium L/min @ 1wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
247.77 vs 228.57 Tiotropium L/min @ 2wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
248.33 vs 228.82 Tiotropium L/min @ 3wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
247.3 vs 226.49 Tiotropium L/min @ 4wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
244.43 vs 227.81 Tiotropium L/min @ 1wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
248.84 vs 227.81 Tiotropium L/min @ 1wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
240.87 vs 228.57 Tiotropium L/min @ 2wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
249.99 vs 228.57 Tiotropium L/min @ 2wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
239.61 vs 228.82 Tiotropium L/min @ 3wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
249.39 vs 228.82 Tiotropium L/min @ 3wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
234.14 vs 226.49 Tiotropium L/min @ 4wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
249.17 vs 226.49 Tiotropium L/min @ 4wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
PEF Weekly Avg Evening 205.236 vs 190.676 placebo L/min10 mcg qd
absolute value · L/min
NCT00782210 · Phase 3
show 15 more results
216.155 vs 195.502 placebo L/min10 mcg qd
NCT00782509 · Phase 3
207.862 vs 190.676 placebo L/min5 mcg qd
NCT00782210 · Phase 3
207.958 vs 195.502 placebo L/min5 mcg qd
NCT00782509 · Phase 3
268.58 vs 249.1 Tiotropium L/min @ 1wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
266.4 vs 247.1 Tiotropium L/min @ 2wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
265.67 vs 249.78 Tiotropium L/min @ 3wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
265.5 vs 246.77 Tiotropium L/min @ 4wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
260.86 vs 249.1 Tiotropium L/min @ 1wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
267.47 vs 249.1 Tiotropium L/min @ 1wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
260.73 vs 247.1 Tiotropium L/min @ 2wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
267.31 vs 247.1 Tiotropium L/min @ 2wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
258.2 vs 249.78 Tiotropium L/min @ 3wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
268.16 vs 249.78 Tiotropium L/min @ 3wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
253.12 vs 246.77 Tiotropium L/min @ 4wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
266.61 vs 246.77 Tiotropium L/min @ 4wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Daytime Rescue Puffs Daily Avg 0.839 vs 1.487 placebo count10 mcg qd
event count · count
NCT00782210 · Phase 3
show 15 more results
0.85 vs 1.363 placebo count @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.967 vs 1.487 placebo count5 mcg qd
NCT00782210 · Phase 3
0.947 vs 1.363 placebo count @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.406 vs 0.437 placebo count @ 1wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.421 vs 0.466 placebo count @ 2wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.407 vs 0.459 placebo count @ 3wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.408 vs 0.479 placebo count @ 4wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.375 vs 0.479 placebo count @ 5wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.378 vs 0.491 placebo count @ 6wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.403 vs 0.499 placebo count @ 7wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.417 vs 0.482 placebo count @ 8wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.396 vs 0.487 placebo count @ 9wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.392 vs 0.48 placebo count @ 10wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.383 vs 0.482 placebo count @ 11wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.393 vs 0.483 placebo count @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
Nighttime Rescue Puffs Daily Avg 1.492 vs 2.283 placebo count10 mcg qd
event count · count
NCT00782210 · Phase 3
show 15 more results
1.312 vs 2.072 placebo count @ 48wk10 mcg qd
NCT00782509 · Phase 3
1.701 vs 2.283 placebo count5 mcg qd
NCT00782210 · Phase 3
1.652 vs 2.072 placebo count @ 48wk5 mcg qd
NCT00782509 · Phase 3
1.222 vs 1.633 placebo count @ 1wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.232 vs 1.677 placebo count @ 2wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.229 vs 1.707 placebo count @ 3wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.239 vs 1.709 placebo count @ 4wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.177 vs 1.71 placebo count @ 5wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.148 vs 1.692 placebo count @ 6wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.139 vs 1.641 placebo count @ 7wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.173 vs 1.628 placebo count @ 8wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.125 vs 1.636 placebo count @ 9wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.108 vs 1.63 placebo count @ 10wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.104 vs 1.63 placebo count @ 11wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.143 vs 1.625 placebo count @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
Patient Global Assessment 3 vs 3.5 placebo score @ 6wk10 mcg qd
absolute value · score
NCT00782210 · Phase 3
show 31 more results
3 vs 3.4 placebo score @ 12wk10 mcg qd
NCT00782210 · Phase 3
3 vs 3.5 placebo score @ 24wk10 mcg qd
NCT00782210 · Phase 3
3.1 vs 3.4 placebo score @ 48wk10 mcg qd
NCT00782210 · Phase 3
2.9 vs 3.3 placebo score @ 6wk10 mcg qd
NCT00782509 · Phase 3
3 vs 3.2 placebo score @ 12wk10 mcg qd
NCT00782509 · Phase 3
2.9 vs 3.3 placebo score @ 24wk10 mcg qd
NCT00782509 · Phase 3
3 vs 3.3 placebo score @ 48wk10 mcg qd
NCT00782509 · Phase 3
3.2 vs 3.4 placebo score @ 6wk10 mcg qd
NCT00796653 · Phase 3
3 vs 3.3 placebo score @ 12wk10 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.3 placebo score @ 24wk10 mcg qd
NCT00796653 · Phase 3
3 vs 3.2 placebo score @ 48wk10 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.4 placebo score @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.3 placebo score @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.1 placebo score @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.1 placebo score @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3 vs 3.5 placebo score @ 6wk5 mcg qd
NCT00782210 · Phase 3
3 vs 3.4 placebo score @ 12wk5 mcg qd
NCT00782210 · Phase 3
3 vs 3.5 placebo score @ 24wk5 mcg qd
NCT00782210 · Phase 3
3.1 vs 3.4 placebo score @ 48wk5 mcg qd
NCT00782210 · Phase 3
3 vs 3.3 placebo score @ 6wk5 mcg qd
NCT00782509 · Phase 3
2.9 vs 3.2 placebo score @ 12wk5 mcg qd
NCT00782509 · Phase 3
3 vs 3.3 placebo score @ 24wk5 mcg qd
NCT00782509 · Phase 3
3.1 vs 3.3 placebo score @ 48wk5 mcg qd
NCT00782509 · Phase 3
3.1 vs 3.4 placebo score @ 6wk5 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.3 placebo score @ 12wk5 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.3 placebo score @ 24wk5 mcg qd
NCT00796653 · Phase 3
3.2 vs 3.2 placebo score @ 48wk5 mcg qd
NCT00796653 · Phase 3
3 vs 3.4 placebo score @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3 vs 3.3 placebo score @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.1 placebo score @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3 vs 3.1 placebo score @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence

+ 93 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Olodaterol's landscape